Tecentriq Indications/Uses

Urothelial carcinoma (UC): Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC: after prior platinum-containing chemotherapy; or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see Pharmacology: Pharmacodynamics under Actions).
Early-stage non-small cell lung cancer (NSCLC): Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC (see Pharmacology: Pharmacodynamics under Actions for selection criteria).
Metastatic NSCLC: Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq (see Pharmacology: Pharmacodynamics under Actions).
Small cell lung cancer (SCLC): Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see Pharmacology: Pharmacodynamics under Actions).
Triple-negative breast cancer (TNBC): Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
Hepatocellular carcinoma (HCC): Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).